Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Prospective Non-randomized Phase I Study Investigating the Safety of CD19 CAR-T Cells in Patients With Refractory/Relapsed AML Expressing CD19.

NCT06649227 is registered in ClinicalTrials.gov with University Hospital, Lille as lead sponsor.

NCT NCT06649227
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06649227 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Prospective Non-randomized Phase I Study Investigating the Safety of CD19 CAR-T Cells in Patients With Refractory/Relapsed AML Expressing CD19.
Lead sponsor
University Hospital, Lille
Phase
Phase 1
Overall status
Recruiting
Start date
July 10, 2025
Completion date
July 10, 2030
Enrollment
5 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

relapsed adult aml